
Sunshine Biopharma Inc.
SBFMNasdaqCIK 1402328HealthcareFiscal year ends Dec 31
Reports and events: 194 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2022-02-0317:31 ET | S-1/A | Registration statement, amended | 0001683168-22-000663 |
| 2022-01-2416:24 ET | S-1/A | Registration statement, amended | 0001683168-22-000418 |
| 2021-12-2208:01 ET | 8-K | 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-21-006502 |
| 2021-11-0916:50 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0001683168-21-005363 |
| 2021-11-0312:36 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-21-005210 |
| 2021-09-0920:52 ET | S-1 | Registration statement | 0001683168-21-004175 |
| 2021-08-0912:01 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001683168-21-003345 |
| 2021-05-1116:26 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001654954-21-005450 |
| 2021-03-3015:24 ET | 10-K | Annual reportPeriod 2020-12-31 | 0001654954-21-003507 |
| 2020-11-1221:02 ET | 10-Q | Quarterly reportPeriod 2020-09-30 | 0001654954-20-012128 |
| 2020-10-1908:01 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001654954-20-011251 |
| 2020-09-1508:36 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001654954-20-010083 |
| 2020-08-3117:42 ET | 10-Q/A | Quarterly report, amendedPeriod 2020-06-30 | 0001654954-20-009628 |
| 2020-08-1913:19 ET | 10-Q | Quarterly reportPeriod 2020-06-30 | 0001654954-20-009340 |
| 2020-06-2413:07 ET | 8-K | 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001654954-20-006915 |
| 2020-06-0309:03 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001654954-20-006273 |
| 2020-05-1815:35 ET | 10-Q | Quarterly reportPeriod 2020-03-31 | 0001654954-20-005714 |
| 2020-05-0118:59 ET | 10-K | Annual reportPeriod 2019-12-31 | 0001654954-20-004731 |
| 2020-04-1311:16 ET | 8-K | 8.01 Other events | 0001654954-20-003982 |
| 2019-11-1314:54 ET | 10-Q | Quarterly reportPeriod 2019-09-30 | 0001654954-19-012832 |
| 2019-08-1513:29 ET | 10-Q | Quarterly reportPeriod 2019-06-30 | 0001654954-19-009672 |
| 2019-07-1916:04 ET | 8-K | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001654954-19-008360 |
| 2019-05-2013:06 ET | 10-Q | Quarterly reportPeriod 2019-03-31 | 0001654954-19-006301 |
| 2019-04-1217:08 ET | 10-K | Annual reportPeriod 2018-12-31 | 0001654954-19-004354 |
| 2019-03-1208:38 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001654954-19-002574 |
| 2018-11-1616:59 ET | 10-Q | Quarterly reportPeriod 2018-09-30 | 0001654954-18-012900 |
| 2018-10-0916:09 ET | S-1 | Registration statement | 0001654954-18-010915 |
| 2018-09-1413:15 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001654954-18-010186 |
| 2018-08-1709:01 ET | 10-Q | Quarterly reportPeriod 2018-06-30 | 0001654954-18-009279 |
| 2018-05-2217:56 ET | 10-Q | Quarterly reportPeriod 2018-03-31 | 0001654954-18-005724 |
| 2018-04-0215:51 ET | 10-K | Annual reportPeriod 2017-12-31 | 0001654954-18-003495 |
| 2018-01-0412:44 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001654954-18-000098 |
| 2017-11-1510:21 ET | 10-Q | Quarterly reportPeriod 2017-09-30 | 0001654954-17-010704 |
| 2017-09-0516:20 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001654954-17-008137 |
| 2017-08-1116:09 ET | 10-Q | Quarterly reportPeriod 2017-06-30 | 0001654954-17-007370 |
| 2017-06-2312:29 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001654954-17-005826 |
| 2017-05-1215:40 ET | 10-Q | Quarterly reportPeriod 2017-03-31 | 0001654954-17-004568 |
| 2017-04-1714:24 ET | 10-K | Annual reportPeriod 2016-12-31 | 0001654954-17-003365 |
| 2016-11-1415:02 ET | 10-Q | Quarterly reportPeriod 2016-09-30 | 0001654954-16-003935 |
| 2016-08-1614:13 ET | 10-Q | Quarterly reportPeriod 2016-06-30 | 0001654954-16-001658 |
| 2016-08-0912:14 ET | 8-K/A | 3.02 Unregistered sale of equity | 0001654954-16-001290 |
| 2016-08-0113:13 ET | 8-K | 3.02 Unregistered sale of equity | 0001654954-16-001078 |
| 2016-05-0916:09 ET | 10-Q | Quarterly reportPeriod 2016-03-31 | 0001354488-16-007274 |
| 2016-03-2515:57 ET | 10-K | Annual reportPeriod 2015-12-31 | 0001354488-16-006700 |
| 2016-03-1414:57 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001654954-16-000160 |
| 2015-12-2814:11 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001354488-15-005669 |
| 2015-11-0414:41 ET | 10-Q | Quarterly reportPeriod 2015-09-30 | 0001354488-15-004810 |
| 2015-10-0912:54 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001354488-15-004592 |
| 2015-08-0616:04 ET | 10-Q | Quarterly reportPeriod 2015-06-30 | 0001354488-15-003598 |
| 2015-08-0411:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001354488-15-003541 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.